In the fourth quarter and full year 2025, ACADIA Pharmaceuticals reported higher revenues and earnings, surpassing US$1.07 billion in annual revenue and US$391.00 million in net income, and issued ...

Acadia Pharmaceuticals' two approved drugs, NUPLAZID and DAYBUE are guided to continue their strong growth trajectories. Read ...

Q4 2025 earnings call recap: 2026 guidance, EBITDA outlook, facility ramp, CapEx discipline, and Medicaid headwinds—read now.

Aristotle Capital Boston, LLC, an investment advisor, released its fourth-quarter investor letter for “Small Cap Equity Fund”. A copy of the letter can be downloaded here. U.S. small-cap equities ...

Acadia Healthcare ACHC shares are up on Wednesday following the company’s announcement of its fourth-quarter and full-year ...

Acadia Healthcare Company, Inc. (NASDAQ:ACHC) said it has named Debra K. Osteen as chief executive officer with immediate effect. Osteen, who previously led the company and served on its board, ...

FRANKLIN, Tenn.--(BUSINESS WIRE)--Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it will release its fourth quarter and year-end 2025 results on Wednesday, February 25, 2026, ...